Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier
30 September 2020 - 11:00PM
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical
company developing a broad portfolio of product candidates
engineered to cross the blood-brain barrier (BBB) for treatment of
neurodegenerative diseases, today announced that it will host a
webinar on transporting biotherapeutics across the BBB on Thursday,
October 15th from 1:00 p.m. to 4:00 p.m. Eastern Time.
The webinar will provide a deep dive on Denali’s BBB transport
vehicle ("TV") technology to increase the exposure of therapeutics
in the brain and review progress on its TV platform therapeutics
portfolio, including ETV:IDS (DNL310), ETV:SGSH, PTV:PGRN,
ATV:TREM2, and oligonucleotide TV (OTV) programs for
neurodegenerative diseases, as well as potential applications
outside of neurodegeneration.
Registration for the live webinar will be accessible on the
investor page of Denali’s website. Following the webinar, a replay
of the program will be available for a limited time and accessible
at the same address.
About Denali’s TV Platform
The BBB is essential in maintaining the brain’s microenvironment
and protecting it from harmful substances and pathogens circulating
in the bloodstream. Historically, the BBB has posed significant
challenges to drug development for central nervous system (CNS)
diseases by preventing most drugs from reaching the brain in
therapeutically relevant concentrations.
Denali’s TV platform is a proprietary technology designed to
effectively deliver large therapeutic molecules such as antibodies,
enzymes, proteins, and oligonucleotides across the BBB after
intravenous administration. The TV technology is based on
engineered Fc fragments that bind to specific natural transport
receptors expressed at the BBB and are delivered to the brain
through receptor mediated transcytosis. Denali research has shown
that in animal models, antibodies and enzymes engineered with the
TV technology have demonstrated more than 10- to 30-fold greater
brain exposure than similar antibodies and enzymes without this
technology. Improved exposure and broad distribution in the brain
may increase therapeutic efficacy by enabling widespread
achievement of therapeutically relevant concentrations of product
candidates. The most advanced program based on the TV technology is
ETV:IDS (DNL310) for Hunter syndrome, currently in a Phase 1/2
study.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a
broad portfolio of product candidates engineered to cross the
blood-brain barrier (BBB) for neurodegenerative diseases. Denali
pursues new treatments by rigorously assessing genetically
validated targets, engineering delivery across the BBB and guiding
development through biomarkers that demonstrate target and pathway
engagement. Denali is based in South San Francisco. For additional
information, please visit www.denalitherapeutics.com.
Investor Relations Contact:
Laura Hansen650-452-2747hansen@dnli.com
Media Contacts:
Lizzie Hyland(646) 495-2706lhyland@gpg.com
or
Morgan Warners(202) 295-0124mwarners@gpg.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024